ZOSTAVAX™ vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0569 | 0.0513 | 0.063 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0501 | 0.0448 | 0.0559 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00678 | -0.00129 | 0.0149 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.976 | 1.32 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.14 | 0.975 | 1.34 | log | ClinicalTrials.gov | |
| Number needed to harm, for one more participant with a serious adverse event on ZOSTAVAX™ than on Placebo | 147 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | ZOSTAVAX™ | All subjects who were vaccinated according to actual treatment received (Zostavax™) and had safety follow-up. | 340 | 5,979 | EG000 | ClinicalTrials.gov |
| Group 2 | Placebo | All subjects who were vaccinated according to actual treatment received (Placebo) and had safety follow-up. | 300 | 5,990 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | Serious AEs reported within 6 months (182 days) postvaccination. Only Serious adverse events were collected in this study. The Other Adverse Events table is not applicable for this study and shows 0/0 for participants affected/at risk | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) | ClinicalTrials.gov |
| NCT number | NCT00550745 | ClinicalTrials.gov |
| Phases | PHASE4 | ClinicalTrials.gov |
| Conditions | Herpes Zoster | ClinicalTrials.gov |
| Interventions | Zoster Vaccine, Live, Comparator: placebo | ClinicalTrials.gov |
| Lead sponsor | Merck Sharp & Dohme LLC | ClinicalTrials.gov |
| Results first posted | 2010-02-02 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00550745?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.